Soufflé Therapeutics, Inc. has closed an oversubscribed $135 million Series B financing led by Juvia Group to advance its lead clinical programs and continued pipeline progress.
Amount Raised
$135 Million
Round Type
Series B
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Soufflé Therapeutics, Inc. announced the close of an oversubscribed $135 million Series B financing. The funding will support the advancement of its lead clinical programs and continued progress on its pipeline. The round saw participation from several leading institutional investors
Quick answer
Soufflé Therapeutics raised $135 Million in a Series B round, dated October 13, 2026. Investors: Juvia Group, TCG Crossover Management, BB Biotech, Fidelity Management & Research Company and Balyasny Asset Management. Soufflé Therapeutics is based in Boston, Massachusetts, United States.
- How much did Soufflé Therapeutics raise?
- Soufflé Therapeutics raised $135 Million in a Series B round on October 13, 2026.
- Who invested in Soufflé Therapeutics?
- Juvia Group, TCG Crossover Management, BB Biotech, Fidelity Management & Research Company and Balyasny Asset Management are named as investors in this round.
- What does Soufflé Therapeutics do?
- Soufflé Therapeutics is a biotech company focused on creating siRNA medicines that are targeted and cell-specific.
- Where is Soufflé Therapeutics based and how big is it?
- Soufflé Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 68 employees.
- Who are the decision-makers at Soufflé Therapeutics?
- Fundz holds 2 contacts at Soufflé Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Soufflé Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- VectorY raised $83M on November 11, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
Who to call at Soufflé Therapeutics, and when
A new round usually means Soufflé Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Soufflé Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Soufflé Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Soufflé Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Soufflé Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSoufflé Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.